ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40908353

Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.

Pistilli B and 45 others. Nat Med, 2025. Cited by 21 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial. Papers, record 40908353. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40908353

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.
PubMed
Journal
Nat Med
PubMed
Year
2025
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Multicenter Study
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
4.51, provisional
iCite
Revised in PubMed
2026-01-27
PubMed

Authors46

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pistilli BBarbarahttps://orcid.org/0000-0002-9184-7199
2Mosele FFernandahttps://orcid.org/0000-0001-7841-2900
3Corcos NNoemie
4Pierotti LLivia
5Pradat YYoann
6Le Bescond LLoic
7Lacroix-Triki MMagalihttps://orcid.org/0000-0002-6641-8536
8Nachabeh GGhada
9Alfaro AAlexia
10Catelain CCyril

1 to 10 of 46Source PubMed

See all 46 authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Breast NeoplasmsMajor topic
ImmunoconjugatesMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Adult
Aged
Female
Humans
Middle Aged
Biomarkers, Tumor
Estrogen Receptor alpha
Receptor, ErbB-3
Receptors, Estrogen
Receptors, Progesterone

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04965766Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerDerived from the trialYes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137,488,289Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.Nat Med2023https://conductscience.org/library/papers/37488289PubMed
223,396,013Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.Nat Biotechnol2013https://conductscience.org/library/papers/23396013PubMed
339,449,023Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells.Cell Commun Signal2024https://conductscience.org/library/papers/39449023PubMed
425,516,281Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol2014https://conductscience.org/library/papers/25516281PubMed
530,423,086fastp: an ultra-fast all-in-one FASTQ preprocessor.Bioinformatics2018https://conductscience.org/library/papers/30423086PubMed
632,330,069HER2-Low Breast Cancer: Pathological and Clinical Landscape.J Clin Oncol2020https://conductscience.org/library/papers/32330069PubMed
734,272,470Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.NPJ Precis Oncol2021https://conductscience.org/library/papers/34272470PubMed
826,182,432Antibody-drug conjugates as novel anti-cancer chemotherapeutics.Biosci Rep2015https://conductscience.org/library/papers/26182432PubMed
937,086,745Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.Lancet2023https://conductscience.org/library/papers/37086745PubMed
1035,168,570MutationalPatterns: the one stop shop for the analysis of mutational processes.BMC Genomics2022https://conductscience.org/library/papers/35168570PubMed

1 to 10 of 56

See all 56 references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42,988,817Antibody-drug conjugates: unpacking toxicity profiles and optimized designs for enhanced safety and antitumor efficacy.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42988817PubMed
42,974,198Evidence and clinical implications of target antigen changes and reassessment after ADC therapy in solid tumors.Front Oncol2026https://conductscience.org/library/papers/42974198PubMed
42,947,802Efficacy and safety of sacituzumab govitecan in metastatic breast cancer: a single-center retrospective cohort study.Front Oncol2026https://conductscience.org/library/papers/42947802PubMed
42,902,326Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.J Hematol Oncol2026https://conductscience.org/library/papers/42902326PubMed
42,900,402Antibody-drug conjugates and tumor immunity in breast cancer.Med Oncol2026https://conductscience.org/library/papers/42900402PubMed
42,855,492A modular framework for antibody-drug conjugate biomarkers.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42855492PubMed
42,839,022Exploring the immunological effects of antibody-drug conjugates.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42839022PubMed
42,820,289Toward targeted therapeutics for lobular breast cancer.J Clin Invest2026https://conductscience.org/library/papers/42820289PubMed
42,820,285Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications.J Clin Invest2026https://conductscience.org/library/papers/42820285PubMed
42,711,696Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.J Hematol Oncol2026https://conductscience.org/library/papers/42711696PubMed

1 to 10 of 23

See all 23 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32,065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
ESR12,099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PATRITUMAB DERUXTECANCHEMBL4594611Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4594611

Source ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40908353

GET https://conductscience.org/api/papers/v1/40908353/authors?page=2

API referenceFor AI assistants